Close
Mays Cancer Center partners with American Cancer Society to increase lung cancer screenings in South Texas
Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, is partnering with the American Cancer Society to spread awareness and encourage more at-risk South Texans to screen for lung cancer.
Mays Cancer Center at UT Health San Antonio identifies possible markers for early metastatic lung cancer
Researchers at Mays Cancer Center at The University of Texas Health Science at San Antonio have identified protein markers that could signal for early development of metastatic lung cancer, providing possibilities for new treatment. The findings already have led to a five-year, $1.6 million grant from the National Cancer Institute of the National Institutes of […]
Mays Cancer Center Partners with Nation’s Top Cancer Organizations to Endorse Initiative to Increase Lung Cancer Screening in the United States
Joint call to action urges individuals, providers and insurers to increase access to and utilization of low-dose CT screening for those at high risk for lung cancer Contact: Eileen Teves, 210-450-7239, tevese@uthscsa.edu SAN ANTONIO (Nov. 1, 2022) – Lung cancer is the leading cause of cancer death in the United States, accounting for almost 25% of […]
Mays Cancer Center awards and honors
A summary of several of the many awards and honors received by Mays Cancer Center and its researchers during Fiscal Year 2022.
Collection of Sputum and Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer (BA002)
The primary objective of this study is to compare Assay results to diagnoses determined by currently accepted standards for lung cancer detection. This will be accomplished by analysis of sputum samples from three cohorts including healthy Participants, high risk Participants, and cancer patient Participants using the Assay as developed in accordance with findings of bioAffinity protocol BA-001 to confirm assay results. Adjustments will be made as necessary to finalize Assay design for clinical trials and commercialization. The secondary objective of this study is to determine optimum methods for collection of sputum samples. Three sputum collection methods used by high risk Participants will be compared. Individuals at high risk for lung cancer will be assigned to one of three sputum collection cohorts including (1) acapella® airway assist device under medical supervision to obtain a single sputum sample; (2) acapella® airway assist device to obtain a sputum sample over a three-day period, and (3) individuals who under medical supervision will collect a single sputum sample assisted by nebulization of between 0.9% to 10% hypertonic saline. Samples will be compared to determine the optimal collection method for sample analysis by CyPath® Lung.
